methaqualone

(redirected from Somnomed)
Also found in: Dictionary, Thesaurus.

methaqualone

 [meth″ah-qua´lōn]
a nonbarbiturate compound formerly used as a sedative and hypnotic; now found only as a drug of abuse. See drug abuse.

methaqualone

(mĕth′ə-kwā′lōn′)
n.
A potentially habit-forming drug, C16H14N2O, formerly used as a sedative and hypnotic.

methaqualone

An addictive Schedule-II hypnotic-sedative quinazolone with barbiturate-like effects which, when it was legal, was used to reduce anxiety and tension. It was a popular drug of abuse, and it was linked to physical or psychologic dependence.

Clinical findings
Delirium, headache, nausea, pyramidal signs, convulsions, renal and cardiac failure; rarely, aplastic anaemia.
 
Route
Oral, injected, sniffed, smoked.
 
Management of overdose
Haemoperfusion.

Toxic range
> 8 µg/mL, serum; > 300 µg/L, urine.
 
T1/2
20–60 hours.
 
Specimen
Serum, random urine.
 
Method
GC.

methaqualone

Quaalude, 'ludes' Substance abuse An addictive Schedule II hypnotic-sedative quinazolone with barbiturate-like effects; methaqualone was a popular drug of abuse and linked to physical or psychologic dependence Clinical Delirium, headache, nausea, pyramidal signs, convulsions, renal and cardiac failure; rarely, aplastic anemia Route Oral, injected, sniffed, smoked Used for Anxiety, tension Management Hemoperfusion. See Controlled drug substance.

methaqualone

a nonbarbiturate hypnotic similar to barbiturates in its effects.
References in periodicals archive ?
A second agreement was entered into by SomnoMed with KwangWoo MeDix Inc.
SomnoMed (ASX:SOM) is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism.
By establishing SomnoMed in Canada, our customers will soon be able to order SomnoDent and SUAD devices from our Leamington, Canada location and benefit from streamlined shipping and a reduction in inter-country shipping fees.
SomnoMed was commercialized on the basis of extensive clinical research.
We are delighted to be partnering with SomnoMed and their national network of quality dentists," said Sleep HealthCenters CEO Paul Valentine.
With the innovative SomnoDent G2 and Somnomed MATRx both now FDA cleared we are able to offer state-of-the-art oral appliance treatment and diagnostic solutions for OSA patients never seen before," says CEO Ralf Barschow.
About SomnoMed SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism.
As part of this partnership, SomnoMed will work with Benco Dental and its representatives to keep customers up-to-date on the latest developments in dental sleep medicine through in-person and online seminars with the SomnoMed Academy.
Our partnership with Benco Dental is significant and uniquely positioned," said Ralf Barschow, Chief Executive Officer of SomnoMed.
By partnering with SomnoMed, we are meeting our customers' needs with an extensive range of products and services from a trusted source.
This is a significant milestone for us as it demonstrates continued strong demand for SomnoDent sleep apnea treatment," said Ralf Barschow, President & CEO of SomnoMed.